- Email: [email protected]
Origin and immunoescape of uterine cervical cancer
Presse Med. 2014; 43: e413–e421 ß 2014 Elsevier Masson SAS All rights reserved.
on line on www.em-consulte.com/revue/lpm www.sciencedirect.com
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
Quarterly Medical Review Origin and immunoescape of uterine cervical cancer Dorien Van hede1,3, Inge Langers1,3, Philippe Delvenne2, Nathalie Jacobs1
1. University of Liège, cellular and molecular immunology, GIGA-Research, 4000 Liège, Belgium 2. University of Liège, experimental pathology, GIGA-Research, 4000 Liège, Belgium
Correspondence: Available online: 4 November 2014
In this issue Viruses associated with skin and mucosal cancers Pierre Coursaget, Tours, France Merkel cell carcinoma: the first human cancer shown be associated with a polyomavirus Mahtab Samimi et al., Tours, France Origin and immunoescape of uterine cervical cancer Dorien Van hede et al., Liège, Belgium HPV in genital cancers (at the exception of cervical cancer) and anal cancers Silvia de Sanjosé et al., Barcelona, Spain Human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma Tina Dalianis, Stockholm, Sweden Cutaneous HPV and skin cancer Rosita Accardi et al., Lyon, France
Nathalie Jacobs, CHU Sart-Tilman, cellular and molecular immunology, University of Liege, B34 +4, 4000 Liège, Belgium. [email protected]
Summary Human papillomavirus associated uterine cervical cancer is an important public health problem since it is classified as the fourth most common cancer in women worldwide with more than 500,000 recorded cases. This review is focused on where and why HPV infection induces cervical cancers and how this virus avoids the host immune response. Immunological therapeutic approaches are also addressed.
E
ven if the global mortality has diminished in the last years, this cancer still kills more than 200,000 patients every year, accounting for more than 7% of all female cancer deaths, mostly in developing countries [1,2]. Oncogenic human papillomaviruses (HPVs) are the primary etiologic agents of cervical cancer, which occurs usually in the transformation zone (TZ) of the cervix [3]. These HPVs belong to the Alphapapillomavirus genus of the Papillomaviridae [4]. Viral HPV genome is detected in almost all cases of cervical cancer with HPV types 16 and 18 causing 70% of them [5]. Persistent infections with one or more of the 15 oncogenic HPVs lead to the development of well-defined preneoplastic lesions or squamous intraepithelial lesions (SILs). Although HPV infections are frequent, most infected patients will clear the virus naturally within two years and more than 80% of the low grade intraepithelial lesions can regress spontaneously. Unfortunately HPV has developed several immunoescape mechanisms allowing persistent infection to progress into cervical neoplasia [6].
Mucosal oncogenic HPVs To date, 174 HPV types are characterized based on the isolation of complete genomes [7,8] They are organized into five major HPV genera – Alpha-, Beta-, Gamma-, Mu-, and Nu-papillomavirus.
tome 43 > n812 > décembre 2014 http://dx.doi.org/10.1016/j.lpm.2014.09.005
These authors contributed equally to this work.
e413
3
D Van hede, I Langers, P Delvenne, N Jacobs
The Alphapapillomavirus genus contains all HPVs for which sufficient evidence qualifies them as oncogenic for humans [9]. They are also classified as cutaneous or mucosal according to which tissues are infected [7]. This review is focused on mucosal oncogenic HPV, which are the causative agents of uterine cervical cancers and are also etiologically associated with other anogenital tumors and head and neck carcinomas [10]. In 2009, an International Agency for Research on Cancer (IARC) Working Group classified 12 oncogenic mucosal HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) also named high-risk HPV. Twelve additional types (HPV 26, 30, 34, 53, 66, 67, 68, 69, 70, 73, 82, 85 and 97) were classified as probably carcinogenic [11]. Other mucosal HPV types in the Alphapapillomavirus genus (e.g. HPV6 and 11) are responsible for genital warts and benign infections and are referred as lowrisk HPVs [4]. The most prevalent HPV type in the uterine cervix (normal exocervix and every grade of cervical lesions including cancer) is HPV16 [7]. In fact, HPV16 is detected in 52 to 58% of cervical cancers in the world and the second most prevalent HPV type in cancer is HPV18 (ranging from 13 to 22%) [12]. A HPV persistent infection is necessary for the development of cancer, but other cofactors are associated with the malignant transformation of cells infected by HPV such as immunosuppression [13], tobacco smoking [14] or sex hormones [15].
Origin of HPV-induced uterine cervical lesions Cellular origin of cervix cancer
e414
Histologically, two types of epithelia are present in normal cervix. The endocervical canal is protected by a monolayer of glandular epithelium, which produces mucus, a barrier against pathogens, whereas the exterior of the cervix is covered, like the vagina, by a squamous epithelium. After puberty, a physiological process of squamous metaplasia leads to replacement of a portion of the endocervical epithelium by squamous epithelium. This region of metaplasia is named the transformation zone or TZ. Most of the uterine cervical cancers are squamous cell carcinoma (SCC). In a minority of cases, cervical adenocarcinoma (AC), which develops from the mucus-producing gland cells of the endocervix, is observed. Determination of the target cell of HPV infection leading to cervical SCC and AC is still not well defined. Since there are two subtypes of cervical cancer, SCC and AC, it was proposed that SCC appears from squamous epithelium whereas AC derives from glandular epithelium [16]. However, some evidences, like the fact that some SCC started in the endocervix, suggested that SCC develops as a result of proliferation of the reserve or basal cells located into the endocervical canal [17]. Those findings have led to advances in the diagnosis of cervix cancer,
particularly for intracervical curettage and Pap smears test [18]. Study of Burghardt and Ostor revealed that almost all cervical preneoplastic lesions arise from the TZ, thereby defining more precisely the anatomical origin of cervical cancer [3]. Later, based on keratin expression shared by several carcinomas, it was proposed that this expression pattern reflects a common progenitor cell that could be the endocervical reserve cell since these cells express the same panel of keratins [19]. On the other hand, patients can present cervical multifocal lesions with different grade of severities. Genetic alteration analysis of these lesions highlighted allele-specific losses suggesting that distant lesions are in fact related and probably share a common precursor cell [20]. With the discovery of the role of oncogenic HPV in cervical cancer and the paradigm that HPVs infect basal keratinocytes trough epithelium disruption [21], the following question emerged: why SCC are more frequent than vaginal cancers. Recently, a small cell population located at the squamocolumnar junction (figure 1) was identified and potentially represents the first cells that are infected by HPV giving rise to intraepithelial lesions and cervix cancer (figure 2) [22]. These cells display particular cuboidal morphology and form a single layer of epithelial cells joining the endocervical glandular epithelium to the TZ. Interestingly, squamocolumnar junction-specific biomarkers (cytokeratin7, AGR2, CD63, MMP7 and GDA) are expressed in almost all high-grade cervical intraepithelial lesions, SCC and AC, suggesting a common cellular origin for all uterine cervical cancers [22] and a particular susceptibility of these cells to oncogenic potential of HPV proteins.
Early proteins E5, E6 and E7 exhibit a variety of oncogenic properties HPV consists of a double-stranded circular DNA genome coding for early and late genes. Early oncoproteins E5, E6 and E7, are responsible for the occurrence of cervical intraepithelial lesions, whereas E1 and E2 early proteins are implicated in the initiation and regulation of the virus cycle, including repression of E6 and E7 proteins [23]. Late genes encode for the two structural proteins, L1 and L2, forming the viral capsid. HPV virions infect basal epithelial cells of the cervix and need the epithelium differentiation process to produce their late proteins in the upper layer of the epithelium. Then, if infection persists, the viral genome can integrate into the host genome inducing overexpression of oncoproteins, by deletion of E1 and E2, and cancerous transformation of infected cells (reviewed in [24]). As already mentioned, one of the classifications of HPVs resides in their capacity to induce or not neoplasia [25]. Although E6 and E7 from low-risk HPVs interact with their respective targets, they induce lower degradation of these compared to E6 and E7 from high-risk HPVs [26,27]. The major transforming activity of oncogenic HPVs resides in the E6 and E7 genes whereas E5 displays weaker transforming properties. tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
Figure 1 Cervical HPV infection cleared by the immune system HPV particles infect epithelial basal cells either through squamous epithelium microabrasion or via SC junction cells (blue epithelial cells). Viral oncoprotein expression induces development of preneoplastic lesions (epithelial cells with orange nucleus). Various innate immune cells are present in uterine cervix. Activated macrophages kill infected keratinocytes by secreting TNF-a and through nitric oxide-dependent mechanisms. They also provide activation signals for T-cells and NK cells. The latter can recognize infected cells and kill them by releasing their cytotoxic granules. Gamma-delta T cells could participate to the regression of intraepithelial lesions using their anti-viral and anti-tumoral activities. In addition, these cells may improve the cell immune response by enhancing Thelper1 CD4 cells. After having capture and process viral antigens, Langerhans and dendritic cells migrate to adjacent lymph node where they present antigenic peptides to CD4 and CD8T cells. Once activated, these adaptive immune cells infiltrate lesions and contribute to HPV-infected cell elimination.
tome 43 > n812 > décembre 2014
recently, heparanase overexpression induced by E6 was described in HPV-positive squamous cell carcinomas [35–37]. This enzyme degrades the extracellular matrix and releases growth factors leading to tumor aggressiveness and invasion [38]. Also, an in vitro study demonstrates that the expression of some E6 isoforms (short forms) decreased anti-oxidant activity of the cells inducing an oxidative stress and subsequent DNA damage [39]. Infected cell proliferation is also enhanced trough E7 protein transforming activities [40]. By binding the complex pRb/ p107/p130, E7 prevents interaction of the complex with the transcription factor E2F resulting in cyclin A and E expressions [41]. More recently, it has also been shown that E2F, by binding to the RRM2 promoter, enhances expression of HIF-1a and VEGF conducting to increased blood vessel density in cervical cancer tissues [42]. In addition, E7 can also abrogate the inhibitory activities of the cyclin-dependent kinase inhibitors p21 and p27
e415
Although the oncoprotein E6 has no enzymatic activities it induces malignancy by interfering with many cellular proteins. The main oncogenic effect of E6 is provided by the binding to an ubiquitin ligase, E6-AP, leading to the degradation of p53, the major protein implicated in the control of the cell growth arrest and apoptosis after DNA damage [28,29]. Moreover, this viral protein actively contributes to keratinocyte immortalization by inducing overexpression of hTERT [30]. Since the amino acid sequence of E6 contains a PDZ binding motif, many cellular proteins containing PDZ domains were identified as potential targets of E6 [31]. The first identified substrates containing a PDZ domain were the human Disc Large (Dlg) and Scribble (Scrib) proteins, two tumor suppressors involved in the cell polarity control [32,33]. Later, studies have shown that degradation of Scrib proceeds via E6-AP-dependent ubiquitination [33], whereas E6-induced degradation of Dlg has been proposed to involve other ubiquitin ligase than E6-AP [34]. More
D Van hede, I Langers, P Delvenne, N Jacobs
Figure 2 Immunoescape of HPVinfected cells Following the viral genome integration into the host genome, viral oncoproteins are overexpressed and induced cancer cells development. Oncoproteins exert several immunosuppressive activities. E5 is responsible for the decreased expression of MHC1 on infected cells rendering CTL unable to recognize their targeted cells. E6 and E7 inhibit interferon production by using different strategies. Migration of LC and DC at affected sites is impaired due to diminished expression of E-cadherin and decreased secretion of TNF-a and MIP3a. Presence of M2 macrophages is increased and these cells induce basement membrane disruption allowing tumor invasion and development of metastasis. Furthermore, M2 macrophages favorize differentiation of naïve T cells in regulatory T cells. Treg cells, as DC and infected keratinocytes, are a substantial source of IL-10 and TGFb that enhance immunosuppression and tumor growth.
e416
enhancing expression of E2F-responsive genes and cdk2 activity [43,44]. In response to DNA damages, E7 upregulates Cdt1 and stops cell-cycle at the G2 checkpoint leading to a process of ‘‘rereplication’’ responsible for polyploidy and genomic instability [45]. The main oncogenic function of E5 is the induction of epithelial hyperplasia by sensitizing cells to EGF [46]. It has been shown that E5 can enhance the amount of epidermal growth factor receptor (EGFR) at cell surface by stabilizing it and by reducing its degradation [47,48] leading to stimulation of the EGFR signaling pathway and hyperproliferation of infected epithelial cells [49,50]. The E5 protein also enhances DNA synthesis [47] and increases the motility and invasiveness of a human keratinocyte cell line [51]. The principal and newly identified targets of HPV16 oncoproteins are shown in table I. Although HPV oncogenic proteins display numerous transformation activities, their expressions are controlled by E1 and E2 gene products [23] and no cervical cancer cells develop as long as the virus is in the form of an episome in the nucleus of the
infected cell. Accidentally, HPV genome can be integrated into the cell genome causing a cut in the E2 gene resulting in the loss of oncoprotein regulation and into cervical cancer cell development. Moreover, E5, E6 and E7 also display immunosuppressive functions (reviewed in [55]) and the persistence of HPV infection, allowing the virus genome integration, is closely depending on the balance between effective immune responses and mechanisms engaged by the virus to escape immune system.
The role of the immune system in HPV infection Clearance of HPV The increased incidence and progression of HPV infections in immunodeficient patients illustrate the importance of the cellmediated immune response in the control of HPV infections [56,57]. The first defense against infections with HPVs and other pathogens is the mechanical barrier of a pluristratified epithelium.
tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
Table I Principal and newly identified targets of HPV16 oncoproteins Biological effect
Molecular targets
References
E6
Suppression of apoptosis
E6-AP/p53, Bak, FADD
[29,52,53]
E6
Immortalization
NFX1-91, NFX1-123 and hTERT
[30,54]
E6
Loss of cell polarity
PDZ-domain-containing proteins
[31]
E6
Cell invasion
Heparanase
[35–37]
E6
Oxidative stress
SOD2, Gpx
[39]
E7
Cell cycle
pRb/p107/p130, p21 and p27
[41,43,44]
E7
Angiogenesis
E2F/RRM2
[42]
E7
Rereplication
Cdt1
[45]
E5
Epithelial hyperplasia
EGFR
[46]
E5
DNA synthesis
c-fos
[47]
E5
Cell motility and invasiveness
laminin receptors, MMP-7, PKC-d
[51]
Furthermore, epithelial cells produce a variety of anti-microbial compounds including a-defensins that block nuclear localization of HPV16 [58]. As already mentioned, the majority of the HPV-infected women will clear the viral infection within two years [6]. The innate cells may play an important role in this process including: macrophages, dendritic cells (DCs), natural killer (NK) cells and gd T cells (reviewed in [59]). Macrophages as well as DCs, are able, at least in vitro, to kill HPV transformed cells [60,61]. More interestingly, NK cells are more numerous in SIL compared to normal exocervix [62]. Like gd T cells and NK T cells, NK cells are innate lymphocytes able to kill virally infected cells or tumor cells lacking the surface expression of MHC Class I molecules or overexpressing stress-inductible MHC Class I-like molecules (reviewed in [63,64]). NK cells are directly activated by HPV particles. Upon this activation, they secrete high amounts of IFN-g and become highly cytotoxic against HPVtransformed cells [62]. However, peripheral blood mononuclear cells from patients with active HPV16 neoplastic disease display a reduced NK cell activity against HPV16 infected keratinocytes [65]. The role of NK T cells is still uncertain because the level of circulating NK T cells is not associated with the severity of infection or progression to cervical cancer [66]. As a second line of defense, the adaptive immunity, induced by antigen presenting cells (APC) through a Th1 response, can eliminate HPV-infected cells via cytotoxic T lymphocytes (CTLs) targeting HPV16 E2, E6 and E7 [67–69]. gd T cells could improve the function of CTLs in the HPV clearance, since they are present in the genital tract and they enhance the Th1 response in the presence of the herpes simplex virus type 2 [70]. In parallel, the specific local humoral immunity of the cervix contributes to the host defense against HPV. In the lamina propria of the
tome 43 > n812 > décembre 2014
endocervix, numerous plasma cells producing IgG and IgA are detected [71]. In animal infection models, cell-mediated immune response is closely followed by seroconversion and production of antibodies against the major capsid protein L1 [72]. In human, seroconversion is detected between 6 and 18 months after the first HPV DNA test in subjects with persistent HPV infection [73]. All these mechanisms of the HPV clearance process are summarized in figure 1.
Evasion mechanisms of HPV to the immune response Despite the fact that the majority of the HPV-infected women will clear the viral infection within two years [6], one of the hallmarks of HPV infection persistence is to evade effective recognition by the immune system. The productive life cycle of the virus restricted to the epithelium induces low inflammation since HPVs are not cytolytic. As already mentioned, TZ is the most vulnerable site to tumorigenesis and this vulnerability could be linked to a significant decreased number of Langerhans cells (LCs) and altered expression of TNF-a and MIP3a compared to the exocervix [74]. In TZ, the expression of IL-10 and TGF-b is more common than in the exocervix, which suggests that this immunosuppressive condition could be a factor that favorizes progression into cancer [75,76]. HPV proteins downregulate innate immune signaling pathways in the infected keratinocytes [77]. The release of the proinflammatory cytokines (especially type I interferons (IFN)-a or -b) is reduced and consequently there is less activation and migration of LCs and less recruitment of stromal DCs and macrophages [78]. Beyond their oncogenic proprieties E6 and E7 proteins induce multiple mechanisms for innate immune evasion. Recently, it is shown that E7 affects the type I IFN response by downregulating activation of TLR9 [79]. E6 protein
e417
Oncoproteins
D Van hede, I Langers, P Delvenne, N Jacobs
also targets the type I IFN pathway by binding to IRF-3 and inhibiting its transcriptional activation function [80]. E6 can also interfere with Tyk2 function, which results in the alteration of the STAT signaling and therefore specifically inhibiting IFN-amediated signaling [81,82]. This inappropriate costimulatory microenvironment in SILs seems to induce deficient function of LC [83]. Moreover, in vitro, E6 and E7 can reduce the surface levels of E-cadherin, which can interfere with LC migration [84,85] and LCs are not activated by the internalization of HPV capsids [86]. In contrast, stromal DCs can be activated and stimulate HPV-specific T cells [87]. Also macrophages can be part of the disease progression. Several studies showed that macrophages are present in the uterine cervix and their number is significantly increased in SILs and SCC compared to normal counterparts. These macrophages in the HPV-associated tumors are mainly M2 macrophages. M2 macrophages in tumors are able to disrupt basement membrane allowing tumor growth and metastasis (reviewed in [88]). They also promote the differentiation of naïve T cells to T-regulatory cells through IL-10 [89,90]. APCs of the cervix uptake and process HPV antigens in order to present them to the B and T cells in the lymph node and initiate an adaptive immune response against HPV infection. Adaptive immune response is also targeted by HPV protein, since E5 protein can downregulate the processing of classical MHC molecules to the cell surface, which results in the avoidance of CTL recognition of infected cells [91]. In poorly differentiated adenocarcinomas, the secretion of immunoglobulins is impaired [92]. All these mechanisms of the immunoevasion, summarized in figure 2, can support the establishment of persistent HPV infections, leading to the induction of cervical cancer. Regarding the effects of HPV oncoproteins on the host immune system, it is clear that the immune response needs to be improved to overcome this immunoescape.
Challenges for immunotherapy of cervical cancer Currently there are two prophylactic vaccines on the market based on the virus-like particles, which target the low risk types HPV-6 and 11 and the oncogenic types HPV16 and 18 (reviewed in [93]). They are highly efficacious against primary infections due to the high titer of specific neutralizing antibodies that they induce but they have no proven benefits
for already infected women and to other oncogenic viruses [94]. To increase the number of HPV targeted by the vaccine and to offer protection against five more HPV types, a nonavalent vaccine is under FDA inspection [95]. To overcome the immunosuppression of the host and to mount an effective immune response that can eliminate HPV-infected and transformed cells, different vaccine strategies have been tested including the use of peptides, proteins, DNA, viral or bacterial vectors and cell-based vaccines that can be combined (reviewed in [96]). Also the synthetic long peptide (SLP) vaccine showed an excellent treatment profile in animals [97]. In patients with advanced or recurrent HPV16-induced gynecological carcinoma, the HPV16-SLP vaccine was well tolerated and induced a broad IFN-g-associated T cell response but induced no tumor regression nor prevented for a progressive disease [98]. Adjuvant immunotherapies can also improve the current treatment. These therapies involve the administration of cytokines, such as GM-CSF or IFN-b. For example, in a phase I clinical trial, application of GM-CSF on the cervix results in a significant increase of antigen presenting cells and infiltration of cytotoxic T-lymphocytes without recruitment of regulatory T cells [99]. Treatments with IFN-b provide also several new insights. IFN-b induces microRNA-129-5p which downregulates HPV-18 E6 and E7 by targeting SP1 in the cervical cancer cells [100]. IFN-b upregulates A3s, which induces hypermutation of HPV16 E2 in the cervical keratinocytes [101]. Finally, IFN-b also seems to induce senescence by affecting the p53 transactivating activity [102]. As already mentioned, CTLs are necessary to eliminate HPVinfected cells [67–69]. These cells need the help of specific CD4+ T cells. Thus, Scholten et al. [103] tested the feasibility to generate HPV16 specific CD4+ T cells using either transfer of either a MHC class I or MHC class II restricted TCR directed against HPV16 antigens. An alternative strategy could be intravaginal immunization with vectors containing HPV epitopes to induce tissue-resident CD8+ T cell responses [104]. Antibody therapy could be also interesting. For example, in animal models, subcutaneous injection of intrabody against E7 of HPV16 blocks tumor growth [105]. All these strategies can be applied to treat patients suffering from cervical cancer and other HPV16 induced malignancies. Disclosure of interest: the authors declare that they have no conflicts of interest concerning this article.
References [1]
e418
[2]
Forouzanfar MH, Foreman KJ, Delossantos AM et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality
[3]
patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403. Burghardt E, Ostor AG. Site and origin of squamous cervical cancer: a histomorphologic study. Obstet Gynecol 1983; 62:117-27.
[4]
[5]
Bernard HU, Burk RD, Chen Z et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive
tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
tome 43 > n812 > décembre 2014
[20] Larson AA, Liao SY, Stanbridge EJ et al. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res 1997;57:4171-6. [21] zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986;2:489-91. [22] Herfs M, Yamamoto Y, Laury A et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012;109:10516-21. [23] Phelps WC, Howley PM. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product. J Virol 1987;61:1630-8. [24] Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nature reviews. Cancer 2007;7:11-22. [25] Doorbar J, Quint W, Banks L et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012;30:F55-70. [26] Heck DV, Yee CL, Howley PM et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992;89:4442-6. [27] Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996;70:4509-16. [28] Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993;13:4918-27. [29] Scheffner M, Huibregtse JM, Vierstra RD et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505. [30] Gewin L, Myers H, Kiyono T et al. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004;18:2269-82. [31] Nguyen ML, Nguyen MM, Lee D et al. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6’s induction of epithelial hyperplasia in vivo. J Virol 2003;77:6957-64. [32] Lee SS, Weiss RS, Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997;94:6670-5. [33] Nakagawa S, Huibregtse JM. Human scribble (Vartul) is targeted for ubiquitinmediated degradation by the high-risk papillomavirus E6 proteins and the E6AP
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
ubiquitin-protein ligase. Mol Cell Biol 2000;20:8244-53. Pim D, Thomas M, Javier R et al. HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 2000;19:719-25. Shinyo Y, Kodama J, Hongo A et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003;14:1505-10. Zeng C, Ke ZF, Luo WR et al. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo. Med Oncol 2013;30:403. Hirshoren N, Bulvik R, Neuman T et al. Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med 2014;18:181-6. Arvatz G, Shafat I, Levy-Adam F et al. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011;30:253-68. Williams VM, Filippova M, Filippov V et al. HPV16 E6* induces oxidative stress and DNA damage. J Virol 2014;88:6751-61. Demers GW, Espling E, Harry JB et al. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol 1996;70:6862-9. Zerfass K, Levy LM, Cremonesi C et al. Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. J Gen Virol 1995;76:1815-20. Wang N, Zhan T, Ke T et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis i n c e r v i c a l c a n c e r. B r J C a n c e r 2014;110:1034-44. Zerfass-Thome K, Zwerschke W, Mannhardt B et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-30. Funk JO, Waga S, Harry JB et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090-100. Fan X, Liu Y, Heilman SA et al. Human papillomavirus E7 induces rereplication in response to DNA damage. J Virol 2013;87:1200-10. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992;7:27-32. Straight SW, Hinkle PM, Jewers RJ et al. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993;67:4521-32.
e419
[6]
cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73. Plummer M, Schiffman M, Castle PE et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or lowgrade squamous intraepithelial lesion. J Infect Dis 2007;195:1582-9. Bzhalava D, Guan P, Franceschi S et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013;445:224-31. de Villiers EM. Cross-roads in the classification of papillomavi ruses. Virology 2013;445:2-10. Bouvard V, Baan R, Straif K et al. A review of human carcinogens – part B: biological agents. Lancet Oncol 2009;10:321-2. zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009;384:260-5. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agents Cancer 2009;4:8. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. Ellerbrock TV, Chiasson MA, Bush TJ et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-7. Cancer ICoESoC. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2005;118:1481-95. Delvenne P, Herman L, Kholod N, Caberg J, Herfs M, Boniver J et al. Role of hormone cofactors in the human papillomavirusinduced carcinogenesis of the uterine cervix. Mol Cell Endocrinol 2007;264:1-5. Marsh M. Original site of cervical carcinoma; topographical relationship of carcinoma of the cervix to the external os and to the squamocolumnar junction. Obstet Gynecol 1956;7:444-52. Howard LJr, Erickson CC, Stoddard LD. A study of the incidence and histogenesis of endocervical metaplasia and intraepithelial carcinoma; observations on 400 uteri removed for non-cervical disease. Cancer 1951;4:1210-23. Beclere C. Cancer du col de l’utérus d’origine intra-cervicale. Gynecol Prat 1954;5:297-308. Smedts F, Ramaekers F, Troyanovsky S et al. Keratin expression in cervical cancer. Am J Pathol 1992;141:497-511.
D Van hede, I Langers, P Delvenne, N Jacobs
e420
[48] Tomakidi P, Cheng H, Kohl A et al. Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes. Eur J Cell Biol 2000;79:407-12. [49] Zhang B, Srirangam A, Potter DA et al. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005;24:2585-8. [50] Kim SH, Oh JM, No JH et al. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009;30:753-7. [51] Kivi N, Greco D, Auvinen P et al. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 2008;27:2532-41. [52] Jackson S, Harwood C, Thomas M et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000;14:3065-73. [53] Garnett TO, Filippova M, Duerksen-Hughes PJ. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006;13:1915-26. [54] Katzenellenbogen RA, Egelkrout EM, VlietGregg P et al. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. J Virol 2007;81:378696. [55] Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nature reviews. Cancer 2002;2:59-65. [56] Fruchter RG, Maiman M, Sedlis A et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996;87:338-44. [57] Abramowitz L, Benabderrahmane D, Ravaud P et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 2007;21:1457-65. [58] Buck CB, Day PM, Thompson CD et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006;103:1516-21. [59] Amador-Molina A, Hernandez-Valencia JF, Lamoyi E et al. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013;5:2624-42. [60] Denis M, Chadee K, Matlashewski GJ. Macrophage killing of human papillomavirus type 16-transformed cells. Virology 1989;170:342-5. [61] Hubert P, Giannini SL, Vanderplasschen A et al. Dendritic cells induce the death of
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
human papillomavirus-transformed keratinocytes. FASEB J 2001;15:2521-3. Renoux VM, Bisig B, Langers I et al. Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 2011;41:3240-52. Reschner A, Hubert P, Delvenne P et al. Innate lymphocyte and dendritic cell crosstalk: a key factor in the regulation of the immune response. Clin Exp Immunol 2008;152:219-26. Langers I, Renoux VM, Thiry M et al. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012;6:73-82. Lee SJ, Cho YS, Cho MC et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001;167:497-504. Molling JW, de Gruijl TD, Glim J et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007;121:1749-55. de Jong A, van der Burg SH, Kwappenberg KM et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9. Welters MJ, de Jong A, van den Eeden SJ et al. Frequent display of human papillomavirus type 16 E6-specific memory tHelper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41. Bourgault Villada I, Moyal Barracco M, Berville S et al. Human papillomavirus 16specific T cell responses in classic HPVrelated vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol 2010;159:45-56. Nishimura H, Yajima T, Kagimoto Y et al. Intraepithelial gammadelta T cells may bridge a gap between innate immunity and acquired immunity to herpes simplex virus type 2. J Virol 2004;78:4927-30. Ogra PL, Yamanaka T, Losonsky GA. Local immunologic defenses in the genital tract. Prog Clin Biol Res 1981;70:381-94. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Gough GW et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999;265:365-74. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423-30. Giannini SL, Hubert P, Doyen J et al. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
development of squamous intraepithelial lesions of the cervix . Int J Cancer 2002;97:654-9. Giannini SL, Al-Saleh W, Piron H et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998;113:183-9. Herfs M, Hubert P, Kholod N et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol 2008;172:1391-402. Karim R, Meyers C, Backendorf C et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011;6 6:e17848. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007;7:79-89. Hasan UA, Zannetti C, Parroche P et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 2013;210:1369-87. Ronco LV, Karpova AY, Vidal M et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-72. Li S, Labrecque S, Gauzzi MC et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferonalpha. Oncogene 1999;18:5727-37. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 2012;4:376-89. Goncalves MA, Soares EG, Fernandes AP et al. Langerhans’ cell count and HLA class II profile in cervical intraepithelial neoplasia in the presence or absence of HIV infection. Eur J Obstet Gynecol Reprod Biol 2004;114:2217. Matthews K, Leong CM, Baxter L et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003;77:8378-85. Caberg JH, Hubert PM, Begon DY et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008;29:1441-7. Fausch SC, Da Silva DM, Rudolf MP et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002;169: 3242-9.
tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
tome 43 > n812 > décembre 2014
[94] Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369: 2161-70. [95] Drolet M, Laprise JF, Boily MC et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014;134:2264-8. [96] Ma B, Maraj B, Tran NP et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012;17:469-92. [97] Vambutas A, DeVoti J, Nouri M et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80. [98] van Poelgeest MI, Welters MJ, van Esch EM et al. HPV16 synthetic long peptide (HPV16SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013;11:88. [99] Hubert P, Doyen J, Capelle X et al. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade
[100]
[101]
[102]
[103]
[104]
[105]
squamous intraepithelial lesions. Am J Reprod Immunol 2010;64:126-36. Zhang J, Li S, Yan Q et al. Interferon-beta induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One 2013;8:e81366. Wang Z, Wakae K, Kitamura K et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol 2014;88:1308-17. Chiantore MV, Vannucchi S, Accardi R et al. Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS One 2012;7:e36909. Scholten KB, Turksma AW, Ruizendaal JJ et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med 2011;9:147. Cuburu N, Graham BS, Buck CB et al. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012;122:4606-20. Accardi L, Paolini F, Mandarino A et al. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer 2014;134:2742-7.
e421
[87] Da Silva DM, Fausch SC, Verbeek JS et al. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 2007;178:7587-97. [88] Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51. [89] Bolpetti A, Silva JS, Villa LL et al. Interleukin10 production by tumor infiltrating macrophages plays a role in human papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27. [90] Lepique AP, Daghastanli KR, Cuccovia IM et al. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009;15:4391-400. [91] Ashrafi GH, Haghshenas M, Marchetti B et al. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006;119:2105-12. [92] Arends JW, Groniowski MM, de Koning Gans HJ et al. Immunohistochemical study of the distribution of secretory component and IgA in the normal and diseased uterine mucosa. Int J Gynecol Pathol 1983;2:171-81. [93] Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73.
on line on www.em-consulte.com/revue/lpm www.sciencedirect.com
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
Quarterly Medical Review Origin and immunoescape of uterine cervical cancer Dorien Van hede1,3, Inge Langers1,3, Philippe Delvenne2, Nathalie Jacobs1
1. University of Liège, cellular and molecular immunology, GIGA-Research, 4000 Liège, Belgium 2. University of Liège, experimental pathology, GIGA-Research, 4000 Liège, Belgium
Correspondence: Available online: 4 November 2014
In this issue Viruses associated with skin and mucosal cancers Pierre Coursaget, Tours, France Merkel cell carcinoma: the first human cancer shown be associated with a polyomavirus Mahtab Samimi et al., Tours, France Origin and immunoescape of uterine cervical cancer Dorien Van hede et al., Liège, Belgium HPV in genital cancers (at the exception of cervical cancer) and anal cancers Silvia de Sanjosé et al., Barcelona, Spain Human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma Tina Dalianis, Stockholm, Sweden Cutaneous HPV and skin cancer Rosita Accardi et al., Lyon, France
Nathalie Jacobs, CHU Sart-Tilman, cellular and molecular immunology, University of Liege, B34 +4, 4000 Liège, Belgium. [email protected]
Summary Human papillomavirus associated uterine cervical cancer is an important public health problem since it is classified as the fourth most common cancer in women worldwide with more than 500,000 recorded cases. This review is focused on where and why HPV infection induces cervical cancers and how this virus avoids the host immune response. Immunological therapeutic approaches are also addressed.
E
ven if the global mortality has diminished in the last years, this cancer still kills more than 200,000 patients every year, accounting for more than 7% of all female cancer deaths, mostly in developing countries [1,2]. Oncogenic human papillomaviruses (HPVs) are the primary etiologic agents of cervical cancer, which occurs usually in the transformation zone (TZ) of the cervix [3]. These HPVs belong to the Alphapapillomavirus genus of the Papillomaviridae [4]. Viral HPV genome is detected in almost all cases of cervical cancer with HPV types 16 and 18 causing 70% of them [5]. Persistent infections with one or more of the 15 oncogenic HPVs lead to the development of well-defined preneoplastic lesions or squamous intraepithelial lesions (SILs). Although HPV infections are frequent, most infected patients will clear the virus naturally within two years and more than 80% of the low grade intraepithelial lesions can regress spontaneously. Unfortunately HPV has developed several immunoescape mechanisms allowing persistent infection to progress into cervical neoplasia [6].
Mucosal oncogenic HPVs To date, 174 HPV types are characterized based on the isolation of complete genomes [7,8] They are organized into five major HPV genera – Alpha-, Beta-, Gamma-, Mu-, and Nu-papillomavirus.
tome 43 > n812 > décembre 2014 http://dx.doi.org/10.1016/j.lpm.2014.09.005
These authors contributed equally to this work.
e413
3
D Van hede, I Langers, P Delvenne, N Jacobs
The Alphapapillomavirus genus contains all HPVs for which sufficient evidence qualifies them as oncogenic for humans [9]. They are also classified as cutaneous or mucosal according to which tissues are infected [7]. This review is focused on mucosal oncogenic HPV, which are the causative agents of uterine cervical cancers and are also etiologically associated with other anogenital tumors and head and neck carcinomas [10]. In 2009, an International Agency for Research on Cancer (IARC) Working Group classified 12 oncogenic mucosal HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) also named high-risk HPV. Twelve additional types (HPV 26, 30, 34, 53, 66, 67, 68, 69, 70, 73, 82, 85 and 97) were classified as probably carcinogenic [11]. Other mucosal HPV types in the Alphapapillomavirus genus (e.g. HPV6 and 11) are responsible for genital warts and benign infections and are referred as lowrisk HPVs [4]. The most prevalent HPV type in the uterine cervix (normal exocervix and every grade of cervical lesions including cancer) is HPV16 [7]. In fact, HPV16 is detected in 52 to 58% of cervical cancers in the world and the second most prevalent HPV type in cancer is HPV18 (ranging from 13 to 22%) [12]. A HPV persistent infection is necessary for the development of cancer, but other cofactors are associated with the malignant transformation of cells infected by HPV such as immunosuppression [13], tobacco smoking [14] or sex hormones [15].
Origin of HPV-induced uterine cervical lesions Cellular origin of cervix cancer
e414
Histologically, two types of epithelia are present in normal cervix. The endocervical canal is protected by a monolayer of glandular epithelium, which produces mucus, a barrier against pathogens, whereas the exterior of the cervix is covered, like the vagina, by a squamous epithelium. After puberty, a physiological process of squamous metaplasia leads to replacement of a portion of the endocervical epithelium by squamous epithelium. This region of metaplasia is named the transformation zone or TZ. Most of the uterine cervical cancers are squamous cell carcinoma (SCC). In a minority of cases, cervical adenocarcinoma (AC), which develops from the mucus-producing gland cells of the endocervix, is observed. Determination of the target cell of HPV infection leading to cervical SCC and AC is still not well defined. Since there are two subtypes of cervical cancer, SCC and AC, it was proposed that SCC appears from squamous epithelium whereas AC derives from glandular epithelium [16]. However, some evidences, like the fact that some SCC started in the endocervix, suggested that SCC develops as a result of proliferation of the reserve or basal cells located into the endocervical canal [17]. Those findings have led to advances in the diagnosis of cervix cancer,
particularly for intracervical curettage and Pap smears test [18]. Study of Burghardt and Ostor revealed that almost all cervical preneoplastic lesions arise from the TZ, thereby defining more precisely the anatomical origin of cervical cancer [3]. Later, based on keratin expression shared by several carcinomas, it was proposed that this expression pattern reflects a common progenitor cell that could be the endocervical reserve cell since these cells express the same panel of keratins [19]. On the other hand, patients can present cervical multifocal lesions with different grade of severities. Genetic alteration analysis of these lesions highlighted allele-specific losses suggesting that distant lesions are in fact related and probably share a common precursor cell [20]. With the discovery of the role of oncogenic HPV in cervical cancer and the paradigm that HPVs infect basal keratinocytes trough epithelium disruption [21], the following question emerged: why SCC are more frequent than vaginal cancers. Recently, a small cell population located at the squamocolumnar junction (figure 1) was identified and potentially represents the first cells that are infected by HPV giving rise to intraepithelial lesions and cervix cancer (figure 2) [22]. These cells display particular cuboidal morphology and form a single layer of epithelial cells joining the endocervical glandular epithelium to the TZ. Interestingly, squamocolumnar junction-specific biomarkers (cytokeratin7, AGR2, CD63, MMP7 and GDA) are expressed in almost all high-grade cervical intraepithelial lesions, SCC and AC, suggesting a common cellular origin for all uterine cervical cancers [22] and a particular susceptibility of these cells to oncogenic potential of HPV proteins.
Early proteins E5, E6 and E7 exhibit a variety of oncogenic properties HPV consists of a double-stranded circular DNA genome coding for early and late genes. Early oncoproteins E5, E6 and E7, are responsible for the occurrence of cervical intraepithelial lesions, whereas E1 and E2 early proteins are implicated in the initiation and regulation of the virus cycle, including repression of E6 and E7 proteins [23]. Late genes encode for the two structural proteins, L1 and L2, forming the viral capsid. HPV virions infect basal epithelial cells of the cervix and need the epithelium differentiation process to produce their late proteins in the upper layer of the epithelium. Then, if infection persists, the viral genome can integrate into the host genome inducing overexpression of oncoproteins, by deletion of E1 and E2, and cancerous transformation of infected cells (reviewed in [24]). As already mentioned, one of the classifications of HPVs resides in their capacity to induce or not neoplasia [25]. Although E6 and E7 from low-risk HPVs interact with their respective targets, they induce lower degradation of these compared to E6 and E7 from high-risk HPVs [26,27]. The major transforming activity of oncogenic HPVs resides in the E6 and E7 genes whereas E5 displays weaker transforming properties. tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
Figure 1 Cervical HPV infection cleared by the immune system HPV particles infect epithelial basal cells either through squamous epithelium microabrasion or via SC junction cells (blue epithelial cells). Viral oncoprotein expression induces development of preneoplastic lesions (epithelial cells with orange nucleus). Various innate immune cells are present in uterine cervix. Activated macrophages kill infected keratinocytes by secreting TNF-a and through nitric oxide-dependent mechanisms. They also provide activation signals for T-cells and NK cells. The latter can recognize infected cells and kill them by releasing their cytotoxic granules. Gamma-delta T cells could participate to the regression of intraepithelial lesions using their anti-viral and anti-tumoral activities. In addition, these cells may improve the cell immune response by enhancing Thelper1 CD4 cells. After having capture and process viral antigens, Langerhans and dendritic cells migrate to adjacent lymph node where they present antigenic peptides to CD4 and CD8T cells. Once activated, these adaptive immune cells infiltrate lesions and contribute to HPV-infected cell elimination.
tome 43 > n812 > décembre 2014
recently, heparanase overexpression induced by E6 was described in HPV-positive squamous cell carcinomas [35–37]. This enzyme degrades the extracellular matrix and releases growth factors leading to tumor aggressiveness and invasion [38]. Also, an in vitro study demonstrates that the expression of some E6 isoforms (short forms) decreased anti-oxidant activity of the cells inducing an oxidative stress and subsequent DNA damage [39]. Infected cell proliferation is also enhanced trough E7 protein transforming activities [40]. By binding the complex pRb/ p107/p130, E7 prevents interaction of the complex with the transcription factor E2F resulting in cyclin A and E expressions [41]. More recently, it has also been shown that E2F, by binding to the RRM2 promoter, enhances expression of HIF-1a and VEGF conducting to increased blood vessel density in cervical cancer tissues [42]. In addition, E7 can also abrogate the inhibitory activities of the cyclin-dependent kinase inhibitors p21 and p27
e415
Although the oncoprotein E6 has no enzymatic activities it induces malignancy by interfering with many cellular proteins. The main oncogenic effect of E6 is provided by the binding to an ubiquitin ligase, E6-AP, leading to the degradation of p53, the major protein implicated in the control of the cell growth arrest and apoptosis after DNA damage [28,29]. Moreover, this viral protein actively contributes to keratinocyte immortalization by inducing overexpression of hTERT [30]. Since the amino acid sequence of E6 contains a PDZ binding motif, many cellular proteins containing PDZ domains were identified as potential targets of E6 [31]. The first identified substrates containing a PDZ domain were the human Disc Large (Dlg) and Scribble (Scrib) proteins, two tumor suppressors involved in the cell polarity control [32,33]. Later, studies have shown that degradation of Scrib proceeds via E6-AP-dependent ubiquitination [33], whereas E6-induced degradation of Dlg has been proposed to involve other ubiquitin ligase than E6-AP [34]. More
D Van hede, I Langers, P Delvenne, N Jacobs
Figure 2 Immunoescape of HPVinfected cells Following the viral genome integration into the host genome, viral oncoproteins are overexpressed and induced cancer cells development. Oncoproteins exert several immunosuppressive activities. E5 is responsible for the decreased expression of MHC1 on infected cells rendering CTL unable to recognize their targeted cells. E6 and E7 inhibit interferon production by using different strategies. Migration of LC and DC at affected sites is impaired due to diminished expression of E-cadherin and decreased secretion of TNF-a and MIP3a. Presence of M2 macrophages is increased and these cells induce basement membrane disruption allowing tumor invasion and development of metastasis. Furthermore, M2 macrophages favorize differentiation of naïve T cells in regulatory T cells. Treg cells, as DC and infected keratinocytes, are a substantial source of IL-10 and TGFb that enhance immunosuppression and tumor growth.
e416
enhancing expression of E2F-responsive genes and cdk2 activity [43,44]. In response to DNA damages, E7 upregulates Cdt1 and stops cell-cycle at the G2 checkpoint leading to a process of ‘‘rereplication’’ responsible for polyploidy and genomic instability [45]. The main oncogenic function of E5 is the induction of epithelial hyperplasia by sensitizing cells to EGF [46]. It has been shown that E5 can enhance the amount of epidermal growth factor receptor (EGFR) at cell surface by stabilizing it and by reducing its degradation [47,48] leading to stimulation of the EGFR signaling pathway and hyperproliferation of infected epithelial cells [49,50]. The E5 protein also enhances DNA synthesis [47] and increases the motility and invasiveness of a human keratinocyte cell line [51]. The principal and newly identified targets of HPV16 oncoproteins are shown in table I. Although HPV oncogenic proteins display numerous transformation activities, their expressions are controlled by E1 and E2 gene products [23] and no cervical cancer cells develop as long as the virus is in the form of an episome in the nucleus of the
infected cell. Accidentally, HPV genome can be integrated into the cell genome causing a cut in the E2 gene resulting in the loss of oncoprotein regulation and into cervical cancer cell development. Moreover, E5, E6 and E7 also display immunosuppressive functions (reviewed in [55]) and the persistence of HPV infection, allowing the virus genome integration, is closely depending on the balance between effective immune responses and mechanisms engaged by the virus to escape immune system.
The role of the immune system in HPV infection Clearance of HPV The increased incidence and progression of HPV infections in immunodeficient patients illustrate the importance of the cellmediated immune response in the control of HPV infections [56,57]. The first defense against infections with HPVs and other pathogens is the mechanical barrier of a pluristratified epithelium.
tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
Table I Principal and newly identified targets of HPV16 oncoproteins Biological effect
Molecular targets
References
E6
Suppression of apoptosis
E6-AP/p53, Bak, FADD
[29,52,53]
E6
Immortalization
NFX1-91, NFX1-123 and hTERT
[30,54]
E6
Loss of cell polarity
PDZ-domain-containing proteins
[31]
E6
Cell invasion
Heparanase
[35–37]
E6
Oxidative stress
SOD2, Gpx
[39]
E7
Cell cycle
pRb/p107/p130, p21 and p27
[41,43,44]
E7
Angiogenesis
E2F/RRM2
[42]
E7
Rereplication
Cdt1
[45]
E5
Epithelial hyperplasia
EGFR
[46]
E5
DNA synthesis
c-fos
[47]
E5
Cell motility and invasiveness
laminin receptors, MMP-7, PKC-d
[51]
Furthermore, epithelial cells produce a variety of anti-microbial compounds including a-defensins that block nuclear localization of HPV16 [58]. As already mentioned, the majority of the HPV-infected women will clear the viral infection within two years [6]. The innate cells may play an important role in this process including: macrophages, dendritic cells (DCs), natural killer (NK) cells and gd T cells (reviewed in [59]). Macrophages as well as DCs, are able, at least in vitro, to kill HPV transformed cells [60,61]. More interestingly, NK cells are more numerous in SIL compared to normal exocervix [62]. Like gd T cells and NK T cells, NK cells are innate lymphocytes able to kill virally infected cells or tumor cells lacking the surface expression of MHC Class I molecules or overexpressing stress-inductible MHC Class I-like molecules (reviewed in [63,64]). NK cells are directly activated by HPV particles. Upon this activation, they secrete high amounts of IFN-g and become highly cytotoxic against HPVtransformed cells [62]. However, peripheral blood mononuclear cells from patients with active HPV16 neoplastic disease display a reduced NK cell activity against HPV16 infected keratinocytes [65]. The role of NK T cells is still uncertain because the level of circulating NK T cells is not associated with the severity of infection or progression to cervical cancer [66]. As a second line of defense, the adaptive immunity, induced by antigen presenting cells (APC) through a Th1 response, can eliminate HPV-infected cells via cytotoxic T lymphocytes (CTLs) targeting HPV16 E2, E6 and E7 [67–69]. gd T cells could improve the function of CTLs in the HPV clearance, since they are present in the genital tract and they enhance the Th1 response in the presence of the herpes simplex virus type 2 [70]. In parallel, the specific local humoral immunity of the cervix contributes to the host defense against HPV. In the lamina propria of the
tome 43 > n812 > décembre 2014
endocervix, numerous plasma cells producing IgG and IgA are detected [71]. In animal infection models, cell-mediated immune response is closely followed by seroconversion and production of antibodies against the major capsid protein L1 [72]. In human, seroconversion is detected between 6 and 18 months after the first HPV DNA test in subjects with persistent HPV infection [73]. All these mechanisms of the HPV clearance process are summarized in figure 1.
Evasion mechanisms of HPV to the immune response Despite the fact that the majority of the HPV-infected women will clear the viral infection within two years [6], one of the hallmarks of HPV infection persistence is to evade effective recognition by the immune system. The productive life cycle of the virus restricted to the epithelium induces low inflammation since HPVs are not cytolytic. As already mentioned, TZ is the most vulnerable site to tumorigenesis and this vulnerability could be linked to a significant decreased number of Langerhans cells (LCs) and altered expression of TNF-a and MIP3a compared to the exocervix [74]. In TZ, the expression of IL-10 and TGF-b is more common than in the exocervix, which suggests that this immunosuppressive condition could be a factor that favorizes progression into cancer [75,76]. HPV proteins downregulate innate immune signaling pathways in the infected keratinocytes [77]. The release of the proinflammatory cytokines (especially type I interferons (IFN)-a or -b) is reduced and consequently there is less activation and migration of LCs and less recruitment of stromal DCs and macrophages [78]. Beyond their oncogenic proprieties E6 and E7 proteins induce multiple mechanisms for innate immune evasion. Recently, it is shown that E7 affects the type I IFN response by downregulating activation of TLR9 [79]. E6 protein
e417
Oncoproteins
D Van hede, I Langers, P Delvenne, N Jacobs
also targets the type I IFN pathway by binding to IRF-3 and inhibiting its transcriptional activation function [80]. E6 can also interfere with Tyk2 function, which results in the alteration of the STAT signaling and therefore specifically inhibiting IFN-amediated signaling [81,82]. This inappropriate costimulatory microenvironment in SILs seems to induce deficient function of LC [83]. Moreover, in vitro, E6 and E7 can reduce the surface levels of E-cadherin, which can interfere with LC migration [84,85] and LCs are not activated by the internalization of HPV capsids [86]. In contrast, stromal DCs can be activated and stimulate HPV-specific T cells [87]. Also macrophages can be part of the disease progression. Several studies showed that macrophages are present in the uterine cervix and their number is significantly increased in SILs and SCC compared to normal counterparts. These macrophages in the HPV-associated tumors are mainly M2 macrophages. M2 macrophages in tumors are able to disrupt basement membrane allowing tumor growth and metastasis (reviewed in [88]). They also promote the differentiation of naïve T cells to T-regulatory cells through IL-10 [89,90]. APCs of the cervix uptake and process HPV antigens in order to present them to the B and T cells in the lymph node and initiate an adaptive immune response against HPV infection. Adaptive immune response is also targeted by HPV protein, since E5 protein can downregulate the processing of classical MHC molecules to the cell surface, which results in the avoidance of CTL recognition of infected cells [91]. In poorly differentiated adenocarcinomas, the secretion of immunoglobulins is impaired [92]. All these mechanisms of the immunoevasion, summarized in figure 2, can support the establishment of persistent HPV infections, leading to the induction of cervical cancer. Regarding the effects of HPV oncoproteins on the host immune system, it is clear that the immune response needs to be improved to overcome this immunoescape.
Challenges for immunotherapy of cervical cancer Currently there are two prophylactic vaccines on the market based on the virus-like particles, which target the low risk types HPV-6 and 11 and the oncogenic types HPV16 and 18 (reviewed in [93]). They are highly efficacious against primary infections due to the high titer of specific neutralizing antibodies that they induce but they have no proven benefits
for already infected women and to other oncogenic viruses [94]. To increase the number of HPV targeted by the vaccine and to offer protection against five more HPV types, a nonavalent vaccine is under FDA inspection [95]. To overcome the immunosuppression of the host and to mount an effective immune response that can eliminate HPV-infected and transformed cells, different vaccine strategies have been tested including the use of peptides, proteins, DNA, viral or bacterial vectors and cell-based vaccines that can be combined (reviewed in [96]). Also the synthetic long peptide (SLP) vaccine showed an excellent treatment profile in animals [97]. In patients with advanced or recurrent HPV16-induced gynecological carcinoma, the HPV16-SLP vaccine was well tolerated and induced a broad IFN-g-associated T cell response but induced no tumor regression nor prevented for a progressive disease [98]. Adjuvant immunotherapies can also improve the current treatment. These therapies involve the administration of cytokines, such as GM-CSF or IFN-b. For example, in a phase I clinical trial, application of GM-CSF on the cervix results in a significant increase of antigen presenting cells and infiltration of cytotoxic T-lymphocytes without recruitment of regulatory T cells [99]. Treatments with IFN-b provide also several new insights. IFN-b induces microRNA-129-5p which downregulates HPV-18 E6 and E7 by targeting SP1 in the cervical cancer cells [100]. IFN-b upregulates A3s, which induces hypermutation of HPV16 E2 in the cervical keratinocytes [101]. Finally, IFN-b also seems to induce senescence by affecting the p53 transactivating activity [102]. As already mentioned, CTLs are necessary to eliminate HPVinfected cells [67–69]. These cells need the help of specific CD4+ T cells. Thus, Scholten et al. [103] tested the feasibility to generate HPV16 specific CD4+ T cells using either transfer of either a MHC class I or MHC class II restricted TCR directed against HPV16 antigens. An alternative strategy could be intravaginal immunization with vectors containing HPV epitopes to induce tissue-resident CD8+ T cell responses [104]. Antibody therapy could be also interesting. For example, in animal models, subcutaneous injection of intrabody against E7 of HPV16 blocks tumor growth [105]. All these strategies can be applied to treat patients suffering from cervical cancer and other HPV16 induced malignancies. Disclosure of interest: the authors declare that they have no conflicts of interest concerning this article.
References [1]
e418
[2]
Forouzanfar MH, Foreman KJ, Delossantos AM et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality
[3]
patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403. Burghardt E, Ostor AG. Site and origin of squamous cervical cancer: a histomorphologic study. Obstet Gynecol 1983; 62:117-27.
[4]
[5]
Bernard HU, Burk RD, Chen Z et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive
tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
tome 43 > n812 > décembre 2014
[20] Larson AA, Liao SY, Stanbridge EJ et al. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res 1997;57:4171-6. [21] zur Hausen H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986;2:489-91. [22] Herfs M, Yamamoto Y, Laury A et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012;109:10516-21. [23] Phelps WC, Howley PM. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product. J Virol 1987;61:1630-8. [24] Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nature reviews. Cancer 2007;7:11-22. [25] Doorbar J, Quint W, Banks L et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012;30:F55-70. [26] Heck DV, Yee CL, Howley PM et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992;89:4442-6. [27] Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996;70:4509-16. [28] Huibregtse JM, Scheffner M, Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993;13:4918-27. [29] Scheffner M, Huibregtse JM, Vierstra RD et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505. [30] Gewin L, Myers H, Kiyono T et al. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004;18:2269-82. [31] Nguyen ML, Nguyen MM, Lee D et al. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6’s induction of epithelial hyperplasia in vivo. J Virol 2003;77:6957-64. [32] Lee SS, Weiss RS, Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997;94:6670-5. [33] Nakagawa S, Huibregtse JM. Human scribble (Vartul) is targeted for ubiquitinmediated degradation by the high-risk papillomavirus E6 proteins and the E6AP
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
ubiquitin-protein ligase. Mol Cell Biol 2000;20:8244-53. Pim D, Thomas M, Javier R et al. HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 2000;19:719-25. Shinyo Y, Kodama J, Hongo A et al. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003;14:1505-10. Zeng C, Ke ZF, Luo WR et al. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo. Med Oncol 2013;30:403. Hirshoren N, Bulvik R, Neuman T et al. Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med 2014;18:181-6. Arvatz G, Shafat I, Levy-Adam F et al. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011;30:253-68. Williams VM, Filippova M, Filippov V et al. HPV16 E6* induces oxidative stress and DNA damage. J Virol 2014;88:6751-61. Demers GW, Espling E, Harry JB et al. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol 1996;70:6862-9. Zerfass K, Levy LM, Cremonesi C et al. Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. J Gen Virol 1995;76:1815-20. Wang N, Zhan T, Ke T et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis i n c e r v i c a l c a n c e r. B r J C a n c e r 2014;110:1034-44. Zerfass-Thome K, Zwerschke W, Mannhardt B et al. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996;13:2323-30. Funk JO, Waga S, Harry JB et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090-100. Fan X, Liu Y, Heilman SA et al. Human papillomavirus E7 induces rereplication in response to DNA damage. J Virol 2013;87:1200-10. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992;7:27-32. Straight SW, Hinkle PM, Jewers RJ et al. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993;67:4521-32.
e419
[6]
cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73. Plummer M, Schiffman M, Castle PE et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or lowgrade squamous intraepithelial lesion. J Infect Dis 2007;195:1582-9. Bzhalava D, Guan P, Franceschi S et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013;445:224-31. de Villiers EM. Cross-roads in the classification of papillomavi ruses. Virology 2013;445:2-10. Bouvard V, Baan R, Straif K et al. A review of human carcinogens – part B: biological agents. Lancet Oncol 2009;10:321-2. zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009;384:260-5. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agents Cancer 2009;4:8. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. Ellerbrock TV, Chiasson MA, Bush TJ et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000;283:1031-7. Cancer ICoESoC. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2005;118:1481-95. Delvenne P, Herman L, Kholod N, Caberg J, Herfs M, Boniver J et al. Role of hormone cofactors in the human papillomavirusinduced carcinogenesis of the uterine cervix. Mol Cell Endocrinol 2007;264:1-5. Marsh M. Original site of cervical carcinoma; topographical relationship of carcinoma of the cervix to the external os and to the squamocolumnar junction. Obstet Gynecol 1956;7:444-52. Howard LJr, Erickson CC, Stoddard LD. A study of the incidence and histogenesis of endocervical metaplasia and intraepithelial carcinoma; observations on 400 uteri removed for non-cervical disease. Cancer 1951;4:1210-23. Beclere C. Cancer du col de l’utérus d’origine intra-cervicale. Gynecol Prat 1954;5:297-308. Smedts F, Ramaekers F, Troyanovsky S et al. Keratin expression in cervical cancer. Am J Pathol 1992;141:497-511.
D Van hede, I Langers, P Delvenne, N Jacobs
e420
[48] Tomakidi P, Cheng H, Kohl A et al. Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes. Eur J Cell Biol 2000;79:407-12. [49] Zhang B, Srirangam A, Potter DA et al. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005;24:2585-8. [50] Kim SH, Oh JM, No JH et al. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009;30:753-7. [51] Kivi N, Greco D, Auvinen P et al. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 2008;27:2532-41. [52] Jackson S, Harwood C, Thomas M et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000;14:3065-73. [53] Garnett TO, Filippova M, Duerksen-Hughes PJ. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ 2006;13:1915-26. [54] Katzenellenbogen RA, Egelkrout EM, VlietGregg P et al. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. J Virol 2007;81:378696. [55] Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nature reviews. Cancer 2002;2:59-65. [56] Fruchter RG, Maiman M, Sedlis A et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996;87:338-44. [57] Abramowitz L, Benabderrahmane D, Ravaud P et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 2007;21:1457-65. [58] Buck CB, Day PM, Thompson CD et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006;103:1516-21. [59] Amador-Molina A, Hernandez-Valencia JF, Lamoyi E et al. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013;5:2624-42. [60] Denis M, Chadee K, Matlashewski GJ. Macrophage killing of human papillomavirus type 16-transformed cells. Virology 1989;170:342-5. [61] Hubert P, Giannini SL, Vanderplasschen A et al. Dendritic cells induce the death of
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
human papillomavirus-transformed keratinocytes. FASEB J 2001;15:2521-3. Renoux VM, Bisig B, Langers I et al. Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol 2011;41:3240-52. Reschner A, Hubert P, Delvenne P et al. Innate lymphocyte and dendritic cell crosstalk: a key factor in the regulation of the immune response. Clin Exp Immunol 2008;152:219-26. Langers I, Renoux VM, Thiry M et al. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012;6:73-82. Lee SJ, Cho YS, Cho MC et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001;167:497-504. Molling JW, de Gruijl TD, Glim J et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007;121:1749-55. de Jong A, van der Burg SH, Kwappenberg KM et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9. Welters MJ, de Jong A, van den Eeden SJ et al. Frequent display of human papillomavirus type 16 E6-specific memory tHelper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41. Bourgault Villada I, Moyal Barracco M, Berville S et al. Human papillomavirus 16specific T cell responses in classic HPVrelated vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol 2010;159:45-56. Nishimura H, Yajima T, Kagimoto Y et al. Intraepithelial gammadelta T cells may bridge a gap between innate immunity and acquired immunity to herpes simplex virus type 2. J Virol 2004;78:4927-30. Ogra PL, Yamanaka T, Losonsky GA. Local immunologic defenses in the genital tract. Prog Clin Biol Res 1981;70:381-94. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Gough GW et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999;265:365-74. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423-30. Giannini SL, Hubert P, Doyen J et al. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
development of squamous intraepithelial lesions of the cervix . Int J Cancer 2002;97:654-9. Giannini SL, Al-Saleh W, Piron H et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin Exp Immunol 1998;113:183-9. Herfs M, Hubert P, Kholod N et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol 2008;172:1391-402. Karim R, Meyers C, Backendorf C et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011;6 6:e17848. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007;7:79-89. Hasan UA, Zannetti C, Parroche P et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 2013;210:1369-87. Ronco LV, Karpova AY, Vidal M et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-72. Li S, Labrecque S, Gauzzi MC et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferonalpha. Oncogene 1999;18:5727-37. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 2012;4:376-89. Goncalves MA, Soares EG, Fernandes AP et al. Langerhans’ cell count and HLA class II profile in cervical intraepithelial neoplasia in the presence or absence of HIV infection. Eur J Obstet Gynecol Reprod Biol 2004;114:2217. Matthews K, Leong CM, Baxter L et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 2003;77:8378-85. Caberg JH, Hubert PM, Begon DY et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008;29:1441-7. Fausch SC, Da Silva DM, Rudolf MP et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002;169: 3242-9.
tome 43 > n812 > décembre 2014
Origin and immunoescape of uterine cervical cancer
VIRUSES ASSOCIATED WITH SKIN AND MUCOSAL CANCERS
tome 43 > n812 > décembre 2014
[94] Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369: 2161-70. [95] Drolet M, Laprise JF, Boily MC et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014;134:2264-8. [96] Ma B, Maraj B, Tran NP et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012;17:469-92. [97] Vambutas A, DeVoti J, Nouri M et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80. [98] van Poelgeest MI, Welters MJ, van Esch EM et al. HPV16 synthetic long peptide (HPV16SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013;11:88. [99] Hubert P, Doyen J, Capelle X et al. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade
[100]
[101]
[102]
[103]
[104]
[105]
squamous intraepithelial lesions. Am J Reprod Immunol 2010;64:126-36. Zhang J, Li S, Yan Q et al. Interferon-beta induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One 2013;8:e81366. Wang Z, Wakae K, Kitamura K et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol 2014;88:1308-17. Chiantore MV, Vannucchi S, Accardi R et al. Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS One 2012;7:e36909. Scholten KB, Turksma AW, Ruizendaal JJ et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med 2011;9:147. Cuburu N, Graham BS, Buck CB et al. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012;122:4606-20. Accardi L, Paolini F, Mandarino A et al. In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16. Int J Cancer 2014;134:2742-7.
e421
[87] Da Silva DM, Fausch SC, Verbeek JS et al. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol 2007;178:7587-97. [88] Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51. [89] Bolpetti A, Silva JS, Villa LL et al. Interleukin10 production by tumor infiltrating macrophages plays a role in human papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27. [90] Lepique AP, Daghastanli KR, Cuccovia IM et al. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009;15:4391-400. [91] Ashrafi GH, Haghshenas M, Marchetti B et al. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006;119:2105-12. [92] Arends JW, Groniowski MM, de Koning Gans HJ et al. Immunohistochemical study of the distribution of secretory component and IgA in the normal and diseased uterine mucosa. Int J Gynecol Pathol 1983;2:171-81. [93] Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-73.